Cargando…
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
Human epidermal growth factor receptor 2 gene (HER2) is focally amplified in approximately 20% of breast cancers. HER2 inhibitors alone are not effective, and sensitizing agents will be necessary to move away from a reliance on heavily toxic chemotherapeutics. We recently demonstrated that the effic...
Autores principales: | Floros, Konstantinos V., Jacob, Sheeba, Kurupi, Richard, Fairchild, Carter K., Hu, Bin, Puchalapalli, Madhavi, E. Koblinski, Jennifer, Dozmorov, Mikhail G., Boikos, Sosipatros A., Scaltriti, Maurizio, Faber, Anthony C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884408/ https://www.ncbi.nlm.nih.gov/pubmed/33589591 http://dx.doi.org/10.1038/s41419-021-03457-6 |
Ejemplares similares
-
Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy
por: Floros, Konstantinos V., et al.
Publicado: (2018) -
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA
por: Fairchild, Carter K., et al.
Publicado: (2021) -
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
por: Kurupi, Richard, et al.
Publicado: (2022) -
MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022) -
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models
por: Jacob, Sheeba, et al.
Publicado: (2022)